Although how much contribution of lipid metabolism to the pathogenesis of IPF is controversial, at least clinical studies have shown that treatments targeting lipid metabolism (LPA1 antagonist, ATX inhibitor) for IPF have a reasonable effect [1,2]. The gene discussed is LPAR1; the disease is idiopathic interstitial pneumonia.